Synlogic (NASDAQ: SYBX) is working at the cross section of biology and engineering, advancing a new class of medicines for patients. Synthetic Biotic medicines are living biotherapeutics, specifically designed to address the underlying drivers of disease.
| Headquarters | Cambridge, MA |
| Website | www.synlogictx.com |
| @synlogic_tx | |
| Pipeline | Phase 2 clinical trials |
| Partners | AbbVie |